Vismodegib In Basal Cell Carcinoma: Added Benefit Not Proven
Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already…